Status:
COMPLETED
Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
Lead Sponsor:
Myrexis Inc.
Conditions:
Refractory Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.
Eligibility Criteria
Inclusion
- Advanced or Metastatic Cancer
- Measurable / Evaluable Disease
- Karnofsky score greater than or equal to 70%
- Adequate Hematology / Organ function
- No Baseline peripheral or central neuropathy above grade 1
Exclusion
- Hypersensitivity to Cremophor EL
- Pregnant or Lactating
- Spinal Cord Compression
- Pre-existing Dementia / Cognitive Disfunction
- Require Neupogen or Neulasta to Maintain Neutrophil Count
- Have Primary Brain Cancer
- Have history of Ischemic Heart Disease
- Have Diabetes
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00394446
Start Date
March 1 2005
End Date
February 1 2008
Last Update
February 13 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
2
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, United States, 84112